Sirtuins & NAD+: The Longevity Proteins Every Physician Should Know

At a Glance

Sirtuins sit at the intersection of everything I care about in clinical longevity practice—metabolism, inflammation, DNA integrity, and mitochondrial function. They are not a single molecule but a family of seven enzymes (SIRT1 through SIRT7) that use NAD+ as a co-substrate to strip acetyl groups from hundreds of downstream proteins. That single biochemical action ripples outward into virtually every hallmark of aging.

What makes sirtuins clinically actionable—rather than just academically interesting—is that their activity is directly coupled to NAD+ availability, and NAD+ availability is something we can influence. NAD+ drops measurably and consistently with age, illness, and metabolic stress. Addressing that decline is one of the most mechanistically coherent strategies in longevity medicine.

What Sirtuins Actually Do

Sirtuins are class III histone deacetylases (HDACs). Unlike class I and II HDACs, which use zinc as a cofactor, sirtuins consume one molecule of NAD+ for every deacetylation reaction, producing nicotinamide and O-acetyl-ADP-ribose as byproducts. This NAD+ dependency is the key to understanding why sirtuin activity mirrors the cell’s metabolic state—they are molecular sensors of energy availability.

The Seven Family Members

Each sirtuin has a preferred subcellular location and substrate profile:

• SIRT1 – Nucleus/cytoplasm. The most studied. Deacetylates p53, FOXO3, NF-κB, and PGC-1α. Governs stress responses, fat mobilization, and inflammation. Activated by caloric restriction and resveratrol.
• SIRT2 – Cytoplasm. Regulates microtubule stability, cell cycle progression, and adipogenesis. Implicated in neurodegeneration.
• SIRT3 – Mitochondrial matrix. The primary mitochondrial deacetylase. Activates antioxidant enzymes (SOD2, catalase) and the TCA cycle. SIRT3 knockout mice show accelerated metabolic syndrome and hearing loss.
• SIRT4 – Mitochondria. Primarily an ADP-ribosyltransferase. Suppresses glutamine metabolism and fatty acid oxidation under nutrient abundance.
• SIRT5 – Mitochondria. Demalonylase and desuccinylase. Fine-tunes the urea cycle and fatty acid β-oxidation.
• SIRT6 – Nucleus. DNA double-strand break repair, telomere maintenance, suppression of NF-κB, glucose homeostasis. SIRT6 overexpression extends lifespan in male mice by ~15%.
• SIRT7 – Nucleolus. Regulates rRNA transcription and protein quality control. Protects against stress-induced apoptosis in the heart.

In clinical terms, SIRT1, SIRT3, and SIRT6 get the most attention because their loss-of-function phenotypes closely mirror human aging and metabolic disease.

The NAD+–Sirtuin Axis: Why It Declines with Age

NAD+ is synthesized through three main routes: the de novo pathway from tryptophan, the Preiss–Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). In young, healthy tissue, the salvage pathway maintains adequate NAD+ concentrations. With age, two things go wrong simultaneously.

First, NAMPT (nicotinamide phosphoribosyltransferase)—the rate-limiting enzyme of the salvage pathway—declines in activity. Second, NAD+ consumers become chronically overactive. CD38, a glycohydrolase expressed on immune cells, is a major NAD+ consumer whose expression rises with age, particularly during chronic low-grade inflammation (“inflammaging”). PARP enzymes, which use NAD+ for DNA repair, are also constitutively activated by the increasing DNA damage load that accumulates in aged cells.

The net effect is that NAD+ tissue concentrations in humans fall roughly 50% between the ages of 40 and 60. Sirtuin activity tracks that decline. The good news: restoring NAD+ pharmacologically or through lifestyle is one of the better-characterized interventions in translational aging research.

How to Restore NAD+ Levels

I use NMN or NR supplementation alongside IV NAD+ infusions for patients with significant metabolic dysfunction, post-viral fatigue, or neurodegenerative risk. The intravenous route bypasses the gut conversion steps and delivers a rapid elevation in tissue NAD+—particularly useful when the goal is rapid sirtuin activation in a clinical context.

SIRT1 and Metabolic Regulation

SIRT1 is the most extensively studied longevity sirtuin and arguably the most clinically tractable. Its downstream targets read like a who’s-who of metabolic regulation:

PGC-1α deacetylation activates mitochondrial biogenesis and fatty acid oxidation. This is the mechanistic link between SIRT1 activation, caloric restriction, and improved mitochondrial density—a hallmark of metabolically healthy aging.

FOXO3 deacetylation shifts cells from apoptosis toward autophagy and antioxidant gene expression. FOXO3 variants are among the most consistently replicated genetic associations with human longevity (centenarian studies, multiple populations).

NF-κB deacetylation (at Lys310 of RelA/p65) reduces transcription of pro-inflammatory cytokines. This is the mechanistic rationale for why SIRT1 activation dampens inflammaging without suppressing acute immune responses—a clinically important distinction.

p53 deacetylation modulates the decision between cell-cycle arrest and apoptosis in response to DNA damage. Low SIRT1 in tumor microenvironments may shift this balance toward checkpoint bypass, explaining SIRT1’s context-dependent role in cancer biology.

Resveratrol—a polyphenol found in red wine—was the original poster child for SIRT1 activation. Early data from David Sinclair’s lab showed resveratrol extending lifespan in yeast and obese mice. Subsequent work revealed that resveratrol activates SIRT1 indirectly via AMPK rather than direct allosteric binding, and that human bioavailability of trans-resveratrol is poor. Pharmaceutical-grade resveratrol preparations and more potent SIRT1 activators (STAC-9c, SRT2104) remain active research areas.

SIRT3: The Mitochondrial Guardian

If SIRT1 is the master regulator of nuclear gene expression in aging, SIRT3 is its mitochondrial counterpart. SIRT3 is the dominant protein deacetylase in the mitochondrial matrix, and its loss phenocopies many features of mitochondrial aging.

SIRT3 activates:

• Superoxide dismutase 2 (SOD2) – the primary mitochondrial antioxidant enzyme
• Isocitrate dehydrogenase 2 (IDH2) – regenerates NADPH for glutathione recycling
• Complex I subunits – improving electron transport chain efficiency and reducing ROS leak
• Long-chain acyl-CoA dehydrogenase (LCAD) – enhancing fatty acid β-oxidation during fasting

SIRT3 knockout mice develop obesity, insulin resistance, steatohepatitis, and accelerated age-related hearing loss. In humans, SIRT3 SNPs associate with longevity in Italian centenarian cohorts. These aren’t subtle effects—SIRT3 loss essentially compresses the mitochondrial aging phenotype into a few years.

Clinically, anything that raises mitochondrial NAD+—exercise, fasting, NMN/NR supplementation—should activate SIRT3. Zone 2 aerobic training is particularly potent, as it maximizes time spent in the fatty acid oxidation state where mitochondrial NAD+ turnover is highest.

SIRT6: DNA Repair and the Epigenetic Clock

SIRT6 has emerged as perhaps the most compelling lifespan-extending sirtuin. Male mice overexpressing SIRT6 live 14–16% longer than controls—an effect attributed primarily to reduced IGF-1 signaling and enhanced DNA double-strand break repair. SIRT6 is the only sirtuin whose overexpression alone extends murine lifespan in both sexes under at least some experimental conditions.

SIRT6’s key functions:

• Telomere maintenance: SIRT6 deacetylates histone H3K9 and H3K56 at telomeres, suppressing telomere dysfunction and the DNA damage response at chromosome ends.
• NF-κB suppression: SIRT6 deacetylates H3K9 at NF-κB target gene promoters, reducing basal inflammatory gene expression.
• HIF-1α suppression: SIRT6 limits the Warburg effect (aerobic glycolysis) by deacetylating HIF-1α co-activators—relevant to both cancer and metabolic disease.
• Base excision repair (BER): SIRT6 directly interacts with PARP1 and stimulates its activity during DNA damage, improving the efficiency of single-strand break repair.

Epigenetic clock analyses (Horvath, GrimAge, DunedinPACE) all capture methylation changes at loci regulated in part by SIRT6. This makes SIRT6 activity a plausible mechanistic driver of the biological aging rate that these clocks measure.

There are no well-tolerated, bioavailable SIRT6-specific activators in clinical use yet, but fucoidan (a sulfated polysaccharide from brown seaweed), quercetin, and UBCS039 have shown preclinical activity. This is an area I expect to move into clinical practice within this decade.

Clinical Strategies: Activating Sirtuins in Practice

Based on the current evidence hierarchy, here is how I approach sirtuin activation in practice:

1. NAD+ repletion first. No sirtuin activator works without the substrate. I assess metabolic age, inflammatory burden, and mitochondrial function before choosing oral versus IV NAD+ delivery.

2. Caloric restriction or time-restricted eating. The most evolutionarily conserved sirtuin activator. Even a 12–16 hour overnight fast consistently elevates SIRT1 and SIRT3 activity via AMPK-mediated NAMPT upregulation.

3. Exercise prescription. Zone 2 training (conversational pace, 150–180 minutes/week) is the most potent lifestyle-based NAD+ intervention I use. Resistance training adds AMPK activation with a different time course.

4. Polyphenol co-factors. Quercetin, fisetin, and trans-resveratrol may provide additive SIRT1/SIRT3 activation, particularly when combined with NAD+ precursors. I do not rely on them as standalone sirtuin activators.

5. CD38 inhibition. Apigenin (celery seed, chamomile) and quercetin inhibit CD38, reducing NAD+ degradation. This is an underappreciated strategy—blocking consumption is complementary to boosting synthesis.

6. Protein quality control. SIRT2 and SIRT7 both participate in proteostasis. A high-quality protein source with adequate leucine (supporting mTORC1 pulsing rather than chronic activation) supports this arm of sirtuin biology.

One practical point: sirtuin activation through caloric restriction and the sirtuin-activating effects of rapamycin (mTOR inhibition → AMPK activation → NAMPT upregulation) may be partially overlapping mechanisms. Patients on low-dose rapamycin protocols should be counseled on synergistic effects and the importance of maintaining adequate NAD+ substrate.

Related Articles

• NAD+ Supplement Guide: NMN, NR, and IV NAD+ Compared — Full breakdown of NAD+ precursors, dosing protocols, and clinical use cases.
• NAD+ vs NMN vs NR: What’s the Difference? — Side-by-side comparison of the three major NAD+ precursors and the evidence behind each.
• Resveratrol: What the Science Actually Says — Honest appraisal of resveratrol’s longevity evidence, bioavailability challenges, and clinical utility.
• Rapamycin for Longevity: A Physician’s Risk-Benefit Analysis — How mTOR inhibition intersects with sirtuin and AMPK pathways.
• Autophagy: How to Trigger Your Body’s Cellular Recycling System — The downstream consequence of sirtuin activation: selective degradation of damaged organelles.

References

1. Haigis MC, Guarente LP. Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20(21):2913-2921. PMID: 17079682
2. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PMID: 24786309
3. Kanfi Y, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218-221. PMID: 22367546
4. Lombard DB, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807-8814. PMID: 17923702
5. Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. PMID: 24360282
6. Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139. PMID: 27304511
7. Satoh A, et al. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013;18(3):416-430. PMID: 24011076